GR1000489B - Αλληλουχιες dna,μορια ανασυνδιασμενου dna και μεθοδοι για την παραγωγη διαλυτων τ4 πρωτεινων. - Google Patents

Αλληλουχιες dna,μορια ανασυνδιασμενου dna και μεθοδοι για την παραγωγη διαλυτων τ4 πρωτεινων.

Info

Publication number
GR1000489B
GR1000489B GR880100579A GR880100579A GR1000489B GR 1000489 B GR1000489 B GR 1000489B GR 880100579 A GR880100579 A GR 880100579A GR 880100579 A GR880100579 A GR 880100579A GR 1000489 B GR1000489 B GR 1000489B
Authority
GR
Greece
Prior art keywords
soluble
methods
dna sequences
proteins
dna molecules
Prior art date
Application number
GR880100579A
Other languages
English (en)
Other versions
GR880100579A (en
Inventor
A Richard Fisher
A Richard Flavell
Walter Gilbert
Theresa R Lio
M John Maraganore
L Vicki Sato
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of GR880100579A publication Critical patent/GR880100579A/el
Publication of GR1000489B publication Critical patent/GR1000489B/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Η εφεύρεση αυτή αναφέρεται σε αλληλουχίες DNA, μόρια ανασυνδυασμένου DNA και μέθοδος για την παραγωγή διαλυτής Τ4 πρωτεινης. Ειδικότερα, η εφεύρεση αυτή αναφέρεται σε αλληλουχίες DNA που χαρακτηρίζονται από το ότι κωδικοποιούν κατ'έκφραση σε κατάλληλο μονοκύτταρο ξενιστή, διαλυτές μορφές Τ4, τον υποδοχέα στην επιφάνεια Τ4 λεμφοκυττάρων ή παράγωγα αυτών. Σύμφωνα με την εφεύρεση αυτή, οι αλληλουχίες DNA, τα μόρια ανασυνδυασμένου DNA και οι μέθοδοι της εφευρέσεως αυτής μπορούν να χρησιμοποιηθούν προς παραγωγή διαλυτών Τ4 απηλλαγμένων ουσιαστικώς από άλλες πρωτείνες ανθρώπινης προέλευσης . Η διαλυτή αυτή πρωτείνη μπορεί κατόπιν, κατά προτίμηση να χρησιμοποιηθεί στις ανοσοθεραπευτικές και διαγνωστικές συνθέσεις και μεθόδους της εφευρέσεως αυτής. Οι διαλυτές με βάση Τ4 ανοσοθεραπευτικές συνθέσεις και μέθοδοι της εφευρέσεως αυτής, είναι χρήσιμες για τη θεραπεία ανοσοανεπαρκών ασθενών που υποφέρουν από ασθένειες προκαλούμενες από μολυσματικούς παράγοντες των οποίων πρωταρχικοί στόχοι είναι Τ4 λεμφοκύτταρα. Σύμφωνα με ένα προτιμούμενο υπόδειγμα, η εφεύρεση αυτή αναφέρεται σε διαλυτές με βάση Τ4 συνθέσεις και μεθόδους που είναι χρήσιμες στην πρόληψη, θεραπεία ή ανίχνευση του συνδρόμου επίκτητης ανοσολογικής ανεπάρκειας συμπλέγματος συνδεομένου με το AIDS και μολύνσεως από HIV. ω
GR880100579A 1987-09-04 1988-09-05 Αλληλουχιες dna,μορια ανασυνδιασμενου dna και μεθοδοι για την παραγωγη διαλυτων τ4 πρωτεινων. GR1000489B (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9432287A 1987-09-04 1987-09-04
US14164988A 1988-01-07 1988-01-07

Publications (2)

Publication Number Publication Date
GR880100579A GR880100579A (en) 1989-06-22
GR1000489B true GR1000489B (el) 1992-07-30

Family

ID=26788733

Family Applications (1)

Application Number Title Priority Date Filing Date
GR880100579A GR1000489B (el) 1987-09-04 1988-09-05 Αλληλουχιες dna,μορια ανασυνδιασμενου dna και μεθοδοι για την παραγωγη διαλυτων τ4 πρωτεινων.

Country Status (12)

Country Link
EP (1) EP0347435A4 (el)
JP (1) JPH02501192A (el)
KR (1) KR890701605A (el)
DK (1) DK216589A (el)
ES (1) ES2013346A6 (el)
GR (1) GR1000489B (el)
IL (1) IL87647A0 (el)
NO (1) NO891818L (el)
NZ (1) NZ226040A (el)
OA (1) OA09625A (el)
PT (1) PT88425B (el)
WO (1) WO1989001940A1 (el)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001304A1 (en) 1986-08-21 1988-02-25 The Trustees Of Columbia University In The City Of Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
US5958678A (en) * 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US6710169B2 (en) 1987-10-02 2004-03-23 Genentech, Inc. Adheson variants
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
ZA887365B (en) * 1987-10-02 1990-05-30 Genentech Inc Adheson variants
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
US6004781A (en) * 1988-01-22 1999-12-21 The General Hospital Corporation Nucleic acid encoding Ig-CD4 fusion proteins
AU3006789A (en) * 1988-02-24 1989-08-24 Smithkline Beckman Corporation Expression of hiv binding proteins
EP0346091A3 (en) * 1988-06-10 1990-09-12 Dana Farber Cancer Institute Method of diagnosis for naturally occurring antibodies to cd4
AU4660789A (en) * 1988-11-23 1990-06-12 Genentech Inc. Polypeptide derivatives
AU5437190A (en) * 1989-04-05 1990-11-05 Upjohn Company, The Soluble cd4 produced in (e. coli)
EP0408372A1 (en) * 1989-07-13 1991-01-16 Smithkline Beecham Corporation Anti-viral therapy
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
US5180820A (en) * 1989-08-30 1993-01-19 Barde Yves Alain Brain-derived neurotrophic factor
JPH0725794B2 (ja) * 1990-03-23 1995-03-22 呉羽化学工業株式会社 新規なペプチド
EP0491888A4 (en) * 1990-05-25 1992-09-02 Biogen, Inc. Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
CA2073031C (en) * 1990-11-27 2002-10-01 Linda C. Burkly Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
CA2080226C (en) 1991-02-08 2004-05-04 Gary A. Beaudry Cd4-gamma2 and cd4-igg2 chimeras
AU1438592A (en) * 1991-02-08 1992-09-07 Progenics Pharmaceuticals, Inc. Cd4-gamma1 and cd4-igg1 chimeras
US7070991B2 (en) 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
US5389529A (en) * 1991-06-12 1995-02-14 Regeneron Pharmaceuticals, Inc. Modified lamβ signal sequence and processes for producing recombinant neurotrophins
GB9219562D0 (en) 1992-03-11 1992-10-28 Prendergast Kennet F Anti-viral peptides
ES2298457T3 (es) * 1994-11-04 2008-05-16 Idexx Laboratories, Inc. Medio para detectar microbios objetivo en una muestra.
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
EP0830368A1 (en) 1995-06-07 1998-03-25 Genta Incorporated Novel carbamate-based cationic lipids
DE69938062T2 (de) 1998-12-31 2009-01-15 Novartis Vaccines and Diagnostics, Inc., Emeryville Modifizierte hiv env polypeptide
US20030194800A1 (en) 2001-08-31 2003-10-16 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2002533124A (ja) 1998-12-31 2002-10-08 カイロン コーポレイション Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CN113209124B (zh) * 2021-02-24 2022-04-15 四川大学 Dna四面体在制备预防和治疗1型糖尿病的药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001304A1 (en) * 1986-08-21 1988-02-25 The Trustees Of Columbia University In The City Of Dna encoding the t cell surface protein t4 and use of fragments of t4 in the treatment of aids
IL83687A (en) * 1987-08-30 1995-03-30 Yeda Res & Dev Pharmaceutical compositions comprising molecular decays and their use in the manufacture of said compositions
NZ226414A (en) * 1987-10-02 1992-07-28 Genentech Inc Cd4 peptide adhesion variants and their preparation and use

Also Published As

Publication number Publication date
PT88425A (pt) 1989-07-31
AU2482988A (en) 1989-03-31
DK216589D0 (da) 1989-05-03
OA09625A (en) 1993-04-30
AU626007B2 (en) 1992-07-23
NZ226040A (en) 1992-02-25
KR890701605A (ko) 1989-12-21
PT88425B (pt) 1992-10-30
EP0347435A4 (en) 1991-11-21
EP0347435A1 (en) 1989-12-27
NO891818D0 (no) 1989-05-02
ES2013346A6 (es) 1990-05-01
IL87647A0 (en) 1989-02-28
NO891818L (no) 1989-07-03
DK216589A (da) 1989-07-04
WO1989001940A1 (en) 1989-03-09
GR880100579A (en) 1989-06-22
JPH02501192A (ja) 1990-04-26

Similar Documents

Publication Publication Date Title
GR1000489B (el) Αλληλουχιες dna,μορια ανασυνδιασμενου dna και μεθοδοι για την παραγωγη διαλυτων τ4 πρωτεινων.
ATE135747T1 (de) Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
CY1110679T1 (el) Νουκλεοτιδικες και πρωτεϊνικες ακολουθιες γονιδιων nogo και μεθοδοι βασιζομενες σε αυτες
CY1108638T1 (el) Πρωτεϊνη συντηξης των hiv ρυθμιστικων/επικουρικων πρωτεϊνων
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
DE2967697D1 (de) Rekombinante dns-molekuele und verfahren zur herstellung derselben.
CY1107626T1 (el) Παραγωγα πυραζολιου για την θεραπεια του hiv
ATE106748T1 (de) Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum.
DE69028951D1 (de) Oligonukleotiden-Sequenzen zur Amplifizierung von HIV-2 und SIV Retrovirusgenomen, ihre Verwendung zur In-vitro-Diagnostik von durch diese Viren verursachten Infektionen
DE59010435D1 (de) Indolocarbazol-Derivate, Verfahren zu deren Herstellung und deren Verwendung
DK0584145T3 (da) Fremgangsmåde til in vitro-diagnosticering af kromosomanomalier, der er forbundet med CMT1a-sygdom
DE3854550D1 (de) HIV-Peptide und Methoden für den Nachweis von HIV.
GR920100570A (el) Παραγωγα 3(2η)-πυριδαζινονης και μεθοδος για την παρασκευη τους.
ATE114478T1 (de) Verfahren zur kontrolle der leukozyten- extravasation.
DE68918563D1 (de) Protease, reverse Transcriptase und Endonuklease von Retroviren und Verfahren zur Herstellung dieser Enzyme.
ES2196157T3 (es) Oligonucleotidos especificos para el virus de la hepatitis c.
Baltimore et al. Production of a discrete, infectious, double-stranded DNA by reverse transcription in virions of Moloney murine leukemia virus
ATE119166T1 (de) An hiv relatierte peptide.
BE1000167A4 (fr) Antigene du virus de l'hepatite b et procede pour sa production.
DE68913212D1 (de) Ein reines faktor i-protein und verfahren zur herstellung.
DE69615015D1 (de) Zusammensetzungen und verfahren zur detektion und behandlung des erworbenen immun-defizienz-syndroms
ATE143373T1 (de) Proteine, vakzine und nucleinsäuren
GR900100691A (el) Νευροτροφικός παράγοντας ακτινωτού.
ATE59856T1 (de) Sor-genprodukt von lymphotropem virus-iii menschlicher t-zellen.
OA08716A (fr) Peptides susceptibles d'être reconnus par des anticorps induits contre des retrovirus d'immunodéficience humaine (virus HIV), leurs applications au diagnostic des infections dues à certains de ces virus et, le cas échéant, à la vaccination contre le sida.